MEDICAL POLICY

Genetic Testing: Inherited Thrombophilias (Medicare Only)

Effective Date: 6/1/2021

Medical Policy Number: 116

Medical Policy Committee Approved Date: 10/17; 12/18; 12/19; 3/2020; 05/2021

6/1/2021

See Policy CPT CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

Medicare only

MEDICARE POLICY CRITERIA

The following Centers for Medicare & Medicaid Service (CMS) guidelines should be utilized for medical necessity coverage determinations. Click the link provided in the table below to access applicable medical necessity criteria. All listed guidelines apply.

<table>
<thead>
<tr>
<th>Service</th>
<th>Medicare Guidelines</th>
</tr>
</thead>
</table>
| Genetic testing for hypercoagulability / thrombophilia | • Local Coverage Determinations (LCD): [L36159](#), MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)¹  
• Local Coverage Article (LCA): [A57424](#), Billing and Coding: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)² |
### MEDICAL POLICY

#### Genetic Testing: Inherited Thrombophilias (Medicare Only)

#### CPT CODES

<table>
<thead>
<tr>
<th>Medicare Only</th>
<th>Prior Authorization Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>81400</td>
<td>Molecular pathology procedure, Level 1 (e.g., identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis) – when used for [N48K variant F2 (coagulation factor 2) (eg, hereditary hypercoagulability), 1199G&gt;A variant F5 (coagulation factor V) (eg, hereditary hypercoagulability)]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicare Only</th>
<th>Not Covered</th>
</tr>
</thead>
<tbody>
<tr>
<td>81240</td>
<td>F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G&gt;A variant</td>
</tr>
<tr>
<td>81241</td>
<td>F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant</td>
</tr>
<tr>
<td>81291</td>
<td>MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)</td>
</tr>
</tbody>
</table>

#### INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

#### REGULATORY STATUS

**Mental Health Parity Statement**

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.
REFERENCES
